Camurus improves ESG rating score by MSCI

Camurus’ commitment to improve the lives of patients with severe and chronic diseases has a clear sustainability perspective. Over the last years, Camurus has worked purposefully to implement an ambitious sustainability agenda with the aim of improving the company’s sustainability performance and contribution to the UN’s Sustainable Development Goals. The company’s focused sustainability efforts are reflected by the improvements seen in different sustainability ratings during the past years.

In a recent rating by MSCI, one of the leading ESG rating companies globally, Camurus' ranking has been improved from A to AA on a scale ranging from CCC (laggard) to AAA (leader). With an AA ranking, considered a leader, Camurus is positioned in the top 20 percent of the 68 rated companies within its industry.*

“Sustainability is at the core at what we do at Camurus, and I am pleased to see that the continued hard work of our teams to improve Camurus’ sustainability performance and framework is being recognized in international ESG ratings.”, says Fredrik Tiberg, President & CEO of Camurus. “It shows we are focusing on the right things as we continue our journey, creating patient and societal benefit through our breakthrough innovations and new products while at the same time minimizing risks and environmental impact throughout the value chain.”

MSCI uses a rules-based methodology to identify industry leaders and laggards according to their exposure to ESG risks and how well they manage those risks relative to peers. Notable is the high rating of Camurus’ governance structure, employee development possibilities and the company’s ability to retain talent, and governance structure related to patients’ safety. 

For more information about Camurus’ sustainability work, see: https://www.camurus.com/sustainability/

For more information about MSCI, see: https://www.msci.com/

About Camurus
Camurus is a Swedish, science-led biopharmaceutical company committed to developing and commercializing innovative, long-acting medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus’ clinical pipeline includes products for the treatment of dependence, pain, cancer and endocrine diseases, which are developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com.

*Data on file

MSCI ESG Research LLC is a Registered Investment Adviser under the Investment Advisers Act of 1940 and a subsidiary of MSCI Inc. Neither MSCI nor any of its products or services recommends, endorses, approves or otherwise expresses any opinion regarding any issuer, securities, financial products or instruments or trading strategies and MSCI’s products or services are not a recommendation to make (or refrain from making) any kind of investment decision and may not be relied on as such, provided that applicable products or services from MSCI ESG Research may constitute investment advice. The use by Camurus of any MSCI ESG Research LLC or its affiliates (“MSCI”) data, and the use of MSCI logos, trademarks, service marks or index names herein, do not constitute a sponsorship, endorsement, recommendation, or promotion of Camurus by MSCI. MSCI services and data are the property of MSCI or its information providers and are provided ‘as-is’ and without warranty. MSCI names and logos are trademarks or sercice marks of MSCI.